Oncology | Novartis

Media Release
Sep 25, 2023
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Media Release
Sep 14, 2023
Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
Story
Sep 08, 2023
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Media Release
Jun 09, 2023
Novartis unveils results from global patient and physician survey disrupting the notion that CML is a solved disease
Media Release
Jun 02, 2023
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Media Release
May 11, 2023
Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
Media Release
Apr 26, 2023
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Media Release
Mar 27, 2023
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Media Release
Mar 17, 2023
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
Media Release
Dec 05, 2022
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
Media Release
Dec 06, 2022
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
Media Release
Dec 13, 2022
Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer